Annals of Nuclear Cardiology
Online ISSN : 2424-1741
Print ISSN : 2189-3926
ISSN-L : 2189-3926
最新号
選択された号の論文の18件中1~18を表示しています
Editor's Page
Special Review Article
  • Ignasi Carrió
    2020 年 6 巻 1 号 p. 6-10
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    In this report, several issues relevant to scientific publishing in the field of medical imaging are described. How the quality of the research in medical imaging is evaluated is presented as well. The need for journals and the role of current metrics to judge the quality of articles and journals are discussed. Several recommendations are given to aspiring authors on how to write scientific articles in this field to help them optimize their chances of having their articles accepted. Recommendations on how to effectively deal with the review process and how to properly communicate with scientific journals are offered in order to facilitate authors' interaction with reviewers and editors of the journals in the field.

Rapid Communication
  • Andrew Van Tosh, Kenneth J. Nichols
    2020 年 6 巻 1 号 p. 11-14
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    The COVID-19 pandemic has altered all aspects of performing medical procedures throughout the world. It is important to stratify patients into categories according to the likelihood that a requested exam will result in a change in acute management. Health care staff should maintain adequate distancing and engage in frequent hand washing, and personnel who are patient-facing should put on PPE at all times. All patient-touching apparatus should be disinfected between patients according to the Infection Control protocols of the institutions. Most labs have chosen to have patients wear surgical masks to afford some level of protection for them. Efforts should be implemented to enable remote reading and remote reporting of study results. The guidelines presented in this paper are based on the currently available information regarding SARS-CoV-2 (COVID-19) viral infections, but it is essential that all laboratories comply with evolving recommendations of their institutions and public health authorities.

Original Articles
  • Takahiro Doi, Tomoaki Nakata, Takahiro Noto, Tomohiro Mita, Satoshi Yu ...
    2020 年 6 巻 1 号 p. 15-26
    発行日: 2020年
    公開日: 2020/08/31
    [早期公開] 公開日: 2020/07/30
    ジャーナル オープンアクセス HTML

    Background: Obesity increases the risk for development of heart failure (HF) but, when present is likely to be related to better outcomes in patients with HF. This study aimed to clarify the paradoxical prognostic values of visceral obesity in association with cardiac sympathetic function in HF patients.

    Methods and Results: A total of 653 consecutive patients with systolic HF who underwent visceral adiposity area (VAA) measurements using a computed tomographic technique were divided into 3 groups: VAA 1, area <80 cm2; VAA 2, area 80–140 cm2; VAA 3, area >140 cm2. Sympathetic innervation was quantified by 123I-MIBG cardiac activity. Patients were followed up for an average of 22 months with a primary endpoint of lethal cardiac events (CE). The CE group (n=200) had a lower late heart-to mediastinum ratio (HMR) and a smaller VAA than those in the non-CE group. Rates of overall CE/HF death were inversely correlated with VAA: 39.2%±6.2% for VAA 1, 27.4%±19.9% for VAA 2 and 24.1%±15.3% for VAA 3. In addition to sudden cardiac death rate, lethal arrhythmic event rate increased in association with visceral fat obesity: 3.0% for VAA 1, 7.5% for VAA 2 and 8.8% for VAA 3. Late HMR identified high-risk sub-populations in each group.

    Conclusion: Visceral obesity has paradoxical prognostic implications in terms of HF mortality and lethal arrhythmic/sudden cardiac death events. Cardiac sympathetic denervation and quantitative visceral adiposity are synergistically associated with overall cardiac mortality, contributing to better risk stratification of HF patients.

  • Shigeru Fukuzawa, Shinichi Okino, Hikaru Ishiwaki, Yo Iwata, Takashi U ...
    2020 年 6 巻 1 号 p. 27-32
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Objective: The bone scan plays an important role for detecting number of conditions relating to bones, including: bone cancer or bone metastasis, bone inflammation. Extraosseous uptake, in particular, myocardial uptake, was observed in some patients examined with the bone scans. Positive uptake of 99mTc-labeled bone radiotracers is associated with cardiac amyloidosis. However, the frequency and cause of positive cardiac 99mTc-MDP uptake have not been fully studied. In this regard, the aim of this study was to assess the frequency and characteristics of patients with high myocardi-al uptake of bone scintigraphy in daily clinical practice setting.

    Methods: We retrospectively analyzed 4180 bone scintigraphies performed in daily clinical practice during 7-years period. The intensity of the myocardial uptake was graded based on a visual scale ranging from 0 to 3 points. Score 0 indicates the absence of uptake. Score 1 defined uptake less than that of bone (referred to as the adjacent rib). Uptake similar to that of bone was classified score 2. Score 3 was defined as uptake greater than that of reference bone. Positive myocardial uptake included a visual score 2 or 3.

    Result: Positive 99mTc-MDP myocardial uptake occurred in 12 patients among 4180 patients (0.3%). 7 of 12 positive scan patients were consistent with amyloidosis confirmed by biopsy. In these patients, the mean age was 75.6±5.2 years old. Ten cases showed biventricular uptake and 2 showed LV uptake only.

    Conclusion: Positive cardiac uptake of bone scintigraphic agents was present in 0.3% of bone scintigraphies in a clinical practice setting. This may be a sign of cardiac amyloidosis involvement which may give the presence of extraosseous bone tracer uptake its own importance and a new role.

  • Hideyuki Miyauchi, Takashi Iimori, Keisuke Hoshi, Masayuki Ohyama, Ken ...
    2020 年 6 巻 1 号 p. 33-38
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Background: Triglyceride (TG) deposit cardiomyovasculopathy (TGCV) is a novel cardiovascular disorder and was recently encoded as an orphan disease in Europe (ORPHA code: 565612). Defective lipolysis results in TG accumulation in the myocardium and coronary arteries in TGCV. The myocardial washout rate (WR) of iodine-123-β-methyl iodophenyl-pentadecanoic acid (BMIPP) is an essential indicator to evaluate myocardial lipolysis in vivo. TGCV is classified into primary and idiopathic type with and without PNPLA2 mutation, respectively. Here, we present the clinical correlation perspectives of TGCV patients in Chiba, Japan, to increase the awareness of this orphan disease and facilitate its diagnosis.

    Methods: We enrolled 234 patients who underwent BMIPP scintigraphy between September 2015 and July 2019. The diagnosis of TGCV was made based on the criteria we reported previously. Blood smear tests were performed for TGCV classification. The distributions of TGCV in each comorbidity were investigated.

    Results: In total, 104 patients were diagnosed with definitive idiopathic TGCV (I-TGCV). They had various comorbid conditions, including heart failure with reduced ejection fraction and multivessel coronary artery disease requiring revascularization. Moreover, the serum TG levels in I-TGCV patients were not high, and there was no correlation between serum TG level and BMIPP WR (n=205, p-value=0.31), supporting the pathophysiological hypothesis of TGCV.

    Conclusion: I-TGCV patients showed multiple coexistence of coronary artery disease, heart failure of unknown etiology, or diabetes mellitus. For patients with such clinical characteristics, BMIPP scintigraphy and calculation of WR should be considered proactively for the diagnosis of TGCV.

  • Emi Tateishi, Keisuke Kiso, Tetsuya Fukuda
    2020 年 6 巻 1 号 p. 39-45
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Background: Myocardial 18F-fluorodeoxyglucose (18F-FDG) uptake is a sign of active inflammation in patients with cardiac sarcoidosis (CS) under the correct circumstance. However, even under the proper preparation, diffuse myocardial 18F-FDG uptake is frequently observed in the failing heart and misleads the CS disease activity. The aim of this study was to establish the diagnostic value of resting myocardial perfusion single photon emission computed tomography (SPECT) for assessing CS disease activity in patients with diffuse myocardial 18F-FDG uptake.

    Methods: We examined 39 patients with either histologically or clinically proven CS. All patients underwent 18F-FDG positron emission tomography (PET) and resting 99mTc-SPECT. The presence of perfusion–metabolic mismatch was evaluated with generating polar maps of 18F-FDG PET and 99mTc-SPECT images.

    Results: Increased myocardial 18F-FDG uptake was observed in 33 (85%) of 39 patients. Focal 18F-FDG uptake was detected in 16 patients and diffuse 18F-FDG uptake was seen in 17 patients. Brain natriuretic peptide (BNP) levels were significantly higher in patients with diffuse 18F-FDG uptake than those with focal 18F-FDG uptake (p=0.002). With comparing polar maps of 18F-FDG PET and 99mTc-SPECT images, 8 of 16 patients with diffuse 18F-FDG uptake and myocardial perfusion defects demonstrated perfusion-metabolic mismatch which represented active inflammatory lesions in CS.

    Conclusions: Simultaneous evaluation of myocardial 18F-FDG PET and 99mTc-SPECT by polar map analysis provides more relevant information for assessing disease activity in CS than 18F-FDG PET images alone. Perfusion–metabolic mismatch might indicate latent active inflammation in CS patients with diffuse myocardial 18F-FDG uptake, who had advanced heart failure.

Editorial Point of View
Review Article - Focus Issue
Cardiac Sarcoidosis Update
  • Masanao Naya, Osamu Manabe
    2020 年 6 巻 1 号 p. 49-52
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Sarcoidosis is a significant disease affecting the heart. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-validated method for identifying significant focal inflammatory sarcoid lesions. The recent progress in image interpretation in nuclear medicine improves the diagnosis and the risk stratification in patients with cardiac sarcoidosis. Especially, metabolic activity, texture analysis, phase analysis, right ventricle assessment, and digital PET/CT are promising methods to assess cardiac sarcoidosis. This review focuses on the latest data analyses and image interpretation used in nuclear medicine to assess cardiac sarcoidosis.

  • Mark I. Travin
    2020 年 6 巻 1 号 p. 53-60
    発行日: 2020年
    公開日: 2020/08/31
    [早期公開] 公開日: 2020/07/30
    ジャーナル オープンアクセス HTML

    Sarcoidosis, a multi-organ inflammatory condition commonly involving the heart and leading to high morbidity and mortality, is increasingly prevalent. PET imaging with 18F-FDG in conjunction with perfusion imaging is increasingly used for diagnosis, disease characterization, and to guide and follow treatment. However, various challenges remain with regard to protocols, interpretation of image findings, and how best to use test results to guide and monitor therapy. Further investigations of the testing technique, as well as better understanding of disease pathophysiology, are needed for better image utility in order to effectively improve patient outcome.

  • David H. Birnie, Niko Tzemos, Pablo B. Nery
    2020 年 6 巻 1 号 p. 61-66
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Introduction: The Japanese Circulation Society (JCS) recently published new guidelines for the diagnosis and treatment of Cardiac Sarcoidosis (CS). There are two other guideline documents, the World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Organ (WASOG) Assessment Instrument created in 1999 and updated in 2014. Also, in 2014, the Heart Rhythm Society (HRS) published their international guideline document. As co-chair of the HRS document I have been invited to compare and contrast the management aspects of the HRS guidelines with the new JCS document.

    Comments: (i) The HRS document recommended a stepwise approach to VT management and the JCS document is somewhat similar; but with some key differences. (ii) The HRS statement suggested that an ICD for CS patients with an indication for a pacemaker “can be useful”. The JCS document take a similar position although with some additional criteria related to National Health Institute Coverage guidelines. (iii) Both HRS and the JCS documents agree that ICDs are recommended in patients with general guideline indications for primary prevention (i.e. LVEF less than 35%). However which additional patients should be considered for ICDs is controversial. The 2016 JCS document is broadly similar, with the major exception that it is recommended that all patients with LVEF 35–50% should have an EP study.

    Conclusion: The Japanese have been leaders in many aspects of CS including in guideline development. It is clear that the future of CS management is bright, with increasing international collaborations and also multiple efforts underway to obtain higher quality data to inform future guidelines.

Review Article
Disease Discovered in Japan and the Role of Nuclear Cardiology
  • Daisuke Tezuka, Yasuhiro Maejima, Tetsuo Sasano, Mitsuaki Isobe
    2020 年 6 巻 1 号 p. 74-80
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Takayasu arteritis (TAK) is classified as large-vessel vasculitis caused by inflammation. It is often difficult to identify on clinical examination, and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) plays an indispensable role in diagnosing TAK by detecting the location and grade of the inflammatory lesions. The clinical utility of 18F-FDG PET has been established by clinical evidence, and 18F-FDG PET was added to the Japanese national health insurance listing in April 2018. In TAK, 18F-FDG uptake shows typical findings and is easily distinguished, except from physiological uptake. Particularly, the clinical significance of 18F-FDG PET is that can present not only with stenosis but also without stenosis in the arteries, which means that therapeutic intervention is possible before irreversible stenosis develops in the arteries. Additionally, 18F-FDG PET has superior diagnostic accuracy because it allows quantitative analysis using the maximum standardized uptake value. The analysis is used for the assessment of disease activity of TAK and can be utilized for therapeutic intervention in case of repeating remission during the follow-up term.

Educational Track
Awards
JSNC Award
JSNC Technologist Award
  • Go Akamatsu, Hideaki Tashima, Yuma Iwao, Miwako Takahashi, Eiji Yoshid ...
    2020 年 6 巻 1 号 p. 95-98
    発行日: 2020年
    公開日: 2020/08/31
    [早期公開] 公開日: 2020/07/30
    ジャーナル オープンアクセス HTML

    Noninvasive quantification of myocardial blood flow with PET is a vital tool for detecting and monitoring of coronary artery disease. However, current standard cylindrical PET scanners are not optimized for cardiac imaging because they are designed mainly for whole-body imaging. In this study, we proposed two compact geometries, the elliptical geometry and the D-shape geometry, for cardiac-dedicated PET systems. We then evaluated their performance compared with a whole-body-size cylindrical geometry by using the Geant4 Monte Carlo simulation toolkit. In the simulation, an elliptical water phantom was scanned for 10-sec, and we calculated the sensitivity and the noise-equivalent count rate (NECR). Subsequently, a digital chest phantom was scanned for 30-sec and the coincidence data were reconstructed by in-house image reconstruction software. We evaluated the image noise in the liver region and the contrast recoveries in the heart region. Even with the limited number of detectors, the proposed compact geometries showed higher sensitivity than the whole-body geometry. The Dshape geometry achieved 47% higher NECR and 44% lower image noise compared with the whole-body cylindrical geometry. However, the contrasts in the hot area obtained by the proposed compact geometries were not as good as that obtained by the whole-body cylindrical geometry. There was no considerable difference in image quality between the elliptical geometry and the D-shape geometry. In conclusion, the compact geometries we have proposed are promising designs for a high-sensitivity and low-cost cardiac-dedicated PET system. A further study using a defect phantom model is required to evaluate the contrast of cold areas.

Guidelines/Recommendations/Statements
  • Kunihisa Kobayashi, Yasuhiko Sakata, Hideyuki Miyauchi, Yoshihiko Iked ...
    2020 年 6 巻 1 号 p. 99-104
    発行日: 2020年
    公開日: 2020/08/31
    ジャーナル オープンアクセス HTML

    Triglyceride deposit cardiomyovasculopathy (TGCV) is a newly identified disease that was discovered in individuals who required cardiac transplantation in Japan in 2008. Defective intracellular lipolysis causes triglyceride (TG) accumulation in the myocardium and coronary artery vascular smooth muscle cells, which results in severe heart failure and coronary artery disease with poor prognosis. A known cause of TGCV is a genetic deficiency of adipose triglyceride lipase (ATGL), a rate-limiting enzyme in the intracellular hydrolysis of TG. TGCV is classified into primary TGCV with ATGL mutations and idiopathic TGCV without ATGL mutations. Since its discovery, the Japan TGCV Study Group has attempted to elucidate its pathophysiology, develop diagnostic procedures, and specific treatment. Myocardial scintigraphy with iodine-123-β-methyl iodophenyl-pentadecanoic acid (123I-BMIPP) is a unique imaging modality for evaluating myocardial lipolysis in vivo. The washout rate of 123I-BMIPP is an essential indicator for the diagnosis of TGCV. Along with our efforts to provide awareness of and insights into this disease concept, we found that the cumulative number of clinically diagnosed patients has reached >200 and the cases are distributed throughout Japan. In addition, we successfully completed three investigator-initiated clinical trials of a potential therapeutic agent (CNT-01) for TGCV, which was assigned by the Ministry of Health, Labour, and Welfare, Japan, under the SAKIGAKE Designation System in June 2020. Here, we provide the Diagnostic Criteria 2020 for TGCV in order to further promote this “rare and intractable disease” project.

feedback
Top